101. Recent landmark studies in follicular lymphoma.
- Author
-
Sorigue M and Sancho JM
- Subjects
- Biomarkers, Tumor, Clinical Trials as Topic, Combined Modality Therapy, Disease Susceptibility, Gene Expression Regulation, Neoplastic, Humans, Lymphoma, Follicular mortality, Neoplasm Staging, Prognosis, Treatment Outcome, Lymphoma, Follicular diagnosis, Lymphoma, Follicular etiology, Lymphoma, Follicular therapy
- Abstract
Follicular lymphoma (FL) is the most common indolent lymphoma. Therapeutic advances in the past decade have improved its prognosis, but some questions remain open, particularly over adapting therapy to each individual patient's disease risk. Several trials and large studies dealing with biological and therapeutic aspects of FL have been published in the past few months and may have immediate or near-future practice-changing implications. These studies include risk-assessment by gene expression profiling, the therapeutic strategy in localized FL, use of obinutuzumab or lenalidomide in the front-line setting, stem cell transplant in early treatment failure and phosphatidylinositol 3-kinase (PI3K) inhibition and chimeric antigen receptor (CAR) T-cells in multiply relapsed disease. This review aims to contextualize these studies, summarize their design and results, assess their impact, highlight related questions that remain unanswered and, finally, provide a personal view as to how they change our approach to non-transformed FL., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF